Welcome to our dedicated page for scPharmaceuticals news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals stock.
scPharmaceuticals Inc. (NASDAQ: SCPH) is a clinical-stage pharmaceutical company dedicated to revolutionizing the administration of infused therapies. Headquartered in Burlington, MA, the company is spearheading advancements in patient care through its proprietary platform that enables subcutaneous administration of treatments traditionally limited to intravenous (IV) delivery. This innovative approach aims not only to improve patient outcomes but also to significantly reduce healthcare costs.
The company’s flagship product, Furoscix, is a patented furosemide formulation designed for subcutaneous use via the wearable, portable sc2Wear Infusor. Furoscix targets the treatment of edema in heart failure patients, offering them a convenient and effective alternative to traditional IV therapies. With a focus on self-administration, scPharmaceuticals is paving the way for outpatient care of acute conditions.
Recent achievements have bolstered scPharmaceuticals’ position in the pharmaceutical landscape. The company generated $6.1 million in product revenue for the first quarter of 2024, a marked increase from $2.1 million in the same period of the previous year. This growth reflects the rising demand for Furoscix and the successful execution of their commercial strategy.
Moreover, scPharmaceuticals is actively pursuing long-term growth initiatives for Furoscix. These include expanding its indication to include NYHA Class IV heart failure patients and chronic kidney disease, both pending FDA review. Another promising development is the initiation of a pharmacokinetic study to support a low-volume auto-injector version of Furoscix, aimed at providing greater flexibility in treatment options.
The company’s financial health remains robust, with strategic investments in research and development, as well as selling, general, and administrative expenses to support its growth trajectory. Despite reporting a net loss of $14.1 million for the first quarter of 2024, compared to $11.2 million for the first quarter of 2023, scPharmaceuticals remains focused on driving forward with its innovative solutions and strategic partnerships.
For more information, please visit www.scPharmaceuticals.com.
scPharmaceuticals reported a net loss of $7.7 million for Q1 2022, compared to $7.1 million in Q1 2021. Cash, cash equivalents, and investments totaled $65.6 million, down from $75.5 million at the end of 2021, but sufficient to fund operations into 2023. The FDA set a PDUFA action date for FUROSCIX at October 8, 2022, with a potential commercial launch in Q4 2022 if approved. The company is ramping up commercial readiness, including finalizing pricing research and distribution partnerships.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that the FDA has accepted its New Drug Application for FUROSCIX, a formulation of furosemide delivered via an on-body infusor, targeting treatment for heart failure-related congestion. The FDA set a PDUFA action date for October 8, 2022. CEO John Tucker highlighted that FUROSCIX addresses a critical healthcare need and may lead to significant cost savings. The company is preparing for a potential Q4 2022 commercial launch contingent on FDA approval.
scPharmaceuticals (Nasdaq: SCPH) has resubmitted its New Drug Application (NDA) for FUROSCIX, aimed at treating decompensated heart failure. The FDA review is anticipated to conclude by Q4 2022, contingent on approval. The company reported that West Pharmaceutical Services has also completed development of related support documentation. CEO John Tucker highlighted the importance of this milestone and noted the promising cost-saving data from the FREEDOM-HF study, suggesting potential market success if approved.
scPharmaceuticals Inc. (SCPH) has completed all testing for FUROSCIX and plans to re-submit its New Drug Application (NDA) by April 15, 2022, aiming for a Q4 2022 commercial launch. The company ended Q4 2021 with $75.5 million in cash and investments, down from $105.3 million in 2020. It reported a net loss of $7.3 million for Q4 2021, slightly better than the $7.8 million loss in Q4 2020. R&D expenses increased to $4.5 million, while G&A expenses decreased to $2.2 million. The company forecasts a net loss of $43 to $48 million for 2022.
BURLINGTON, Mass., Feb. 16, 2022 – scPharmaceuticals (Nasdaq: SCPH) announced that John Tucker, CEO, will present at the 42nd Annual Cowen Healthcare Conference on March 8 at 1:30 PM EST. The company focuses on optimizing therapies and reducing healthcare costs through innovative products, particularly in outpatient care for heart failure and infectious diseases. A live webcast of the presentation will be available on the company's website. For more information about scPharmaceuticals, visit www.scpharmaceuticals.com.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 4:20pm EDT. The presentation aims to highlight the company's innovative approach to developing products that reduce healthcare costs and improve patient care. scPharmaceuticals focuses on outpatient care for acute conditions, particularly in heart failure and infectious diseases. A live webcast will be available on their investor relations website.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that John Tucker, president & CEO, will participate virtually in two upcoming investor conferences. The first event is the 11th Annual LifeSci Partners Corporate Access Event 2022, scheduled for January 5-7, 2022. Attendees can register and request one-on-one meetings via the provided link. The second event is the H.C. Wainwright Virtual BioConnect 2022 Conference, taking place from January 10-13, 2022, with a webcast available on-demand starting January 10 at 7am EST.
scPharmaceuticals Inc. (SCPH) announced successful testing of commercial devices required by the FDA for FUROSCIX. The NDA resubmission is expected in Q1 2022 due to COVID-19-related delays, but this will not affect the anticipated Q4 2022 launch, if approved. The company ended Q3 2021 with $85 million in cash, projecting sufficient funds into 2023. The net loss for Q3 2021 was reduced to $6.6 million compared to $9 million the previous year. The 2021 net loss guidance has been revised down to $29-31 million.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that its CEO, John Tucker, will present at the Jefferies London Healthcare Conference on November 17, 2021, at 9:25 EDT / 2:25 GMT. The event will take place in-person from November 16-17 and virtually on November 18-19. A live webcast of the presentation will be available under the Investor Relations section on the Company's website.
scPharmaceuticals focuses on developing products that enhance outpatient care for acute conditions, particularly in heart failure and infectious diseases.
scPharmaceuticals (SCPH) reported positive results from the FREEDOM-HF clinical trial showing significant reductions in heart failure-related healthcare costs for patients treated with FUROSCIX®. The study, presented at the HFSA Annual Meeting, found 30-day HF-related costs were $17,753 lower for FUROSCIX patients compared to a historical comparator group. The company plans to resubmit its New Drug Application (NDA) for FUROSCIX in Q4 2021, backed by over $90 million in financing. No serious adverse events were recorded during the study.
FAQ
What is the current stock price of scPharmaceuticals (SCPH)?
What is the market cap of scPharmaceuticals (SCPH)?
What is scPharmaceuticals Inc.?
What is Furoscix?
Where is scPharmaceuticals headquartered?
How much revenue did scPharmaceuticals generate in Q1 2024?
What are the future plans for Furoscix?
What are the benefits of scPharmaceuticals' platform?
What recent financial results did scPharmaceuticals report?
What is the sc2Wear Infusor?
Who are the key contacts for more information?
What is scPharmaceuticals' approach to outpatient care?
